MoneyWorks4Me

ANG Lifesciences India informs about updates

13 Sep 2021 Evaluate

Pursuant to Regulation 30 of SEBI (Listing Obligations & Disclosure Requirements) Regulations, 2015 ANG Lifesciences India has informed that the company has already crossed 200 cr revenue milestone and going forward, the company is expecting similar robust growth in coming quarters. The Company is expected to post turnover around Rs 400-450 cr. with expected IT in measurable terms Rs 15 cr approx in F.Y. 2021-22. Also, the Company has been able to show handsome growth backed by persistent and focused efforts by the management in its goal of maintaining the growth trend on going forward.

The above information is a part of company’s filings submitted to BSE.

Peers
Company Name CMP
Sun Pharma. Inds. 1805.10
Dr. Reddys Labs. 1202.70
Cipla 1344.90
Lupin 2018.50
Zydus Lifesciences 1137.00
View more..